Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF neoadjuvant chemotherapy to enable minimally invasive surgery without routine adjuvant radiotherapy for HPV-positive oropharyngeal cancer
jRCT1041220029Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Pathological complete response rate. Started Oct 2022; status: active, not recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on jRCT1041220029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041220029.